Cardiovascular drug marketplace will be jam-packed by year-end with inexpensive generic alternatives for scarcely all CV drug classes. Is it an opening for novel new developments?
New York, NY (PRWEB) Aug 28, 2012
A tellurian personality in comprehensive, integrated medical and scholarship information database platforms, Medmeme, LLC., expelled a syndicated TrendsmemeTM Report: Cardiology describing a extensive standing of a hypertension indication, treatments, and drug market. An shocking intensity impact of this denote is a tie with other critical diseases (diabetes, stroke, metabolic syndrome, and quite a widespread of obesity). Contribution to preventing a collision march of sum illness weight in a mixed illness areas could be an critical event for curative firms in a altogether cardiovascular diagnosis marketplace.
The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately 68 million people 18+ years old, over one-third of a U.S. population, has hypertension. It finds 48 million people with hypertension (70%) perceived drug treatment, nonetheless usually about half (46% or 31 million people of a sum race with hypertension) has their blood vigour sufficient controlled. And, since hypertension is a wordless condition, many people sojourn undiagnosed—and therefore untreated. Recent annual U. S. health caring costs associated to hypertension are estimated to be approximately $47 billion.
The Medmeme news presents sum of a altogether cardiovascular marketplace describing how it will be jam-packed by year-end with inexpensive general alternatives for scarcely all pivotal drug classes – including hypertension, congestive heart failure, and hyperlipidemia – and how heading hypertension companies have placed poignant concentration on fluctuating a life cycles of their stream drug franchises by line extensions in a form of double and triple combinations of timeless drugs. Fixed-dose therapies from graphic drug classes might be an softened approach to accommodate a needs of several subpopulations of patients within this extended healing category, and maybe beyond.
There are also several new drugs with novel mechanisms in late-stage clinical trials for cardiovascular disease discussed in a report, including renin inhibitors for hypertension, CETP inhibitors for hyperlipidemia, and a accumulation of approaches for strident heart failure. For hypertension alone, a charts and graphs from a Medmeme database prove that there has been a high turn of activity in medical assembly presentations and medical biography articles published on new developments for a hypertension indication. For a many new 3 years there were some-more than 6,600 assembly presentations and some-more than 2,600 articles focusing on hypertension.
The many active companies presenting hypertension information during meetings and in journals were: Abbott, AstraZeneca, Bristol-Myers Squibb, Pfizer, Merck, and Novartis. Other companies active in a healing difficulty discussed in a news are: Actelion, Boehringer Ingelheim, Cardiorentis, Cytokinetics/Amgen, Daiichi-Sankyo, Isis/Genzyme, Janssen Pharmaceuticals/Bayer, and Takeda. Other associated topics of stress reported from a database were a considerations of genetics, lifestyle, peculiarity of life, diabetes, aged patients, and obesity, as they describe to cardiovascular disease.
The syndicated TrendsmemeTM Report: Cardiology can be purchased separately, or, along with other MedMeme reports in a new series, such as TrendsmemeTM Report: Metabolic Disease, during ignored pricing. To learn more, hit Medmeme, or see a website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595